“Pediatric-inspired” B-ALL trials
| Trial . | No. of patients . | Age (years), median (range) . | CR (%) . | OS (%) . | EFS (%) . | DFS (%) . | Duration of follow-up . | AlloHSCT . |
|---|---|---|---|---|---|---|---|---|
| JALSG 202-U | 139 | 19 (16-24) | 97 | 74 | - | 71 | 4 year | t(4;11) |
| DFC1 01-1756 | 92 | 28 (18-50) | 86 | 70 | - | 71 | 4 year | t(4;11), +8, Ph+ |
| DFCI 06-254 | 110 | 32 (18-50) | 89 | 75 | - | 73 | 3 year | t(4;11), +8, Ph+ |
| UKALL 2003 | 229 | 16-24 | 97 | 76.4 | 72.3 | - | 5 year | |
| MDACC aBFM | 106 | 22 (13-39) | 93 | 53 | - | 60 | 5 year | t(4;11) or MRD+ |
| NOPHO ALL 2008 | 221 | 26 (18-45) | - | 78 | 74 | - | 5 year | D29 MRD >5% or D79 > 0.1% |
| GRAALL 2005 | 787 | 36 (18-60) | 92 | 58.5 | 52 | - | 5 year | High risk or MRD+ |
| CALGB10403 | 295 | 24 (17-39) | 89 | 73 | 59 | 66 | 3 year | |
| ALLRE08 PETHEMA | 89 | 20 (15-29) | 95 | 74 | 62 | 65 | 5 year | MRD+ |
| ALL06 | 86 | 22 (15-39) | 90.2 | 74.9 | - | 72.8 | 3 year | t(4;11), MRD+, poor steroid response or WBC >100 |
| GIMEMA LAL-1308 | 76 | 23 (18-35) | 92 | 60.3 | - | 60.4 | 4 year | No CR at D33, pro-B ALL or WBC >100, t(4;11), MRD+ |
| Trial . | No. of patients . | Age (years), median (range) . | CR (%) . | OS (%) . | EFS (%) . | DFS (%) . | Duration of follow-up . | AlloHSCT . |
|---|---|---|---|---|---|---|---|---|
| JALSG 202-U | 139 | 19 (16-24) | 97 | 74 | - | 71 | 4 year | t(4;11) |
| DFC1 01-1756 | 92 | 28 (18-50) | 86 | 70 | - | 71 | 4 year | t(4;11), +8, Ph+ |
| DFCI 06-254 | 110 | 32 (18-50) | 89 | 75 | - | 73 | 3 year | t(4;11), +8, Ph+ |
| UKALL 2003 | 229 | 16-24 | 97 | 76.4 | 72.3 | - | 5 year | |
| MDACC aBFM | 106 | 22 (13-39) | 93 | 53 | - | 60 | 5 year | t(4;11) or MRD+ |
| NOPHO ALL 2008 | 221 | 26 (18-45) | - | 78 | 74 | - | 5 year | D29 MRD >5% or D79 > 0.1% |
| GRAALL 2005 | 787 | 36 (18-60) | 92 | 58.5 | 52 | - | 5 year | High risk or MRD+ |
| CALGB10403 | 295 | 24 (17-39) | 89 | 73 | 59 | 66 | 3 year | |
| ALLRE08 PETHEMA | 89 | 20 (15-29) | 95 | 74 | 62 | 65 | 5 year | MRD+ |
| ALL06 | 86 | 22 (15-39) | 90.2 | 74.9 | - | 72.8 | 3 year | t(4;11), MRD+, poor steroid response or WBC >100 |
| GIMEMA LAL-1308 | 76 | 23 (18-35) | 92 | 60.3 | - | 60.4 | 4 year | No CR at D33, pro-B ALL or WBC >100, t(4;11), MRD+ |
alloHCT, allogeneic hematopoietic stem cell transplantation; MRD, measurable residual disease.
Adapted from Carobolante et al.2